Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 6/20 | 0.64 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20730230 | 0.89 | CYP4F2 (0.68) | CYP4F2CYP4A11KMT2APOLBALDH1A1 | |
| SCHEMBL22071049 | 0.88 | CYP4F2 (0.82) | CYP4F2CYP4A11KMT2APOLBALDH1A1 | |
| SCHEMBL20730225 | 0.87 | CYP4F2 (0.65) | CYP4F2CYP4A11KMT2APOLBALDH1A1 | |
| SCHEMBL22098326 | 0.86 | CYP4F2 (0.67) | CYP4F2CYP4A11KMT2APOLBALDH1A1 | |
| SCHEMBL22070550 | 0.86 | CYP4F2 (0.67) | CYP4F2CYP4A11KMT2APOLBALDH1A1 | |
| SCHEMBL22070545 | 0.84 | CYP4F2 (0.59) | CYP4F2CYP4A11KMT2APOLBALDH1A1 | |
| SCHEMBL6630883 | 0.84 | CYP4F2 (0.56) | CYP4F2CYP4A11KMT2APOLBALDH1A1 | |
| SCHEMBL12660944 | 0.84 | CYP4F2 (0.64) | CYP4F2CYP4A11KMT2APOLBALDH1A1 | |
| SCHEMBL9838425 | 0.83 | CYP4F2 (0.62) | CYP4F2CYP4A11DRD2DRD3 | |
| SCHEMBL1019684 | 0.83 | CYP4F2 (0.62) | CYP4F2CYP4A11DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| WO-2020162612-A1 | PYRIDINE COMPOUND SUBSTITUTED BY HETEROARYL | 大正製薬株式会社 | 2020-08-13 | — | — | WO | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885KMT2A 813/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885KMT2A 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.